

Abstracts

flare over the last 3 months (31% vs. 26%) among those who had transferred to adult rheumatology vs. those who had not. Those who remained in paediatric care were significantly more likely to have seen a rheumatologist in the past year (94% v. 68%, $p = 0.002$) and more likely to be taking immunosuppressive medications (89% v. 34%, $p < 0.001$).

Conclusions Many individuals in this cohort of young adults with cSLE continue with active lupus. In spite of similar disease activity among those who had left paediatric care and those who had not, young adults who had transferred to adult care were significantly less likely to access routine rheumatology care or take immunosuppressive medication, and more likely to encounter difficulty obtaining health insurance coverage. Improving access to adult rheumatology care may be important to prevent poor health outcomes in cSLE.

Acknowledgements Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number 5K23AR066064-03. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

photosensitivity (81%), malar rash (63%) and mucosal ulcers (56%) were the most prevalent SLE features. Only 9 (23%) of patients had low complement C3 or C4 levels, 6 (15%) had cytopenias, and 2 (5%) had elevated levels of anti-dsDNA. The majority of patients were managed with antimalarials (86%), with 8/40 (20%) also using methotrexate; 18/40 (45%) were on treatment with IVIG and 6/40 (15%) were on treatment with belimumab. Disease activity was low (SLEDAI score ≤ 2) in 37/40 (93%) at the last noted follow-up assessment. In the four patients for whom sera was available for testing, levels of BLyS(BAFF) were elevated relative to those noted in 20 control patients without autoimmunity or immunodeficiency, but less than that noted in 20 SLE patients without noted humoral immunodeficiency.

Conclusion SLE may be a presenting feature of patients with humoral immunodeficiency. Serum immunoglobulin levels and assessment of the response to pneumococcal vaccination for patients with low or low normal serum IgG levels should be included as part of the evaluation for suspected SLE. Favourable outcomes are seen in the context of standard of care treatment for SLE combined with immunoglobulin replacement therapy and/or belimumab.

CE-42 SLE PRESENTING IN ASSOCIATION WITH HUMORAL IMMUNODEFICIENCY

Duncan Harmon, Tracy Hwangpo, Harry Schroeder, **W Winn Chatham***. Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham

10.1136/lupus-2016-000179.120

Rational Humoral immunodeficiency syndromes including common variable immune deficiency (CVID) are not uncommonly associated with autoimmune features seen in SLE. Studies were undertaken at an academic centre managing both disorders to determine the relative prevalence, clinical and immunologic features, and outcomes of SLE associated with humoral immunodeficiency.

Methods A retrospective review of records identified using an electronic medical record search of diagnosis codes for SLE and hypogammaglobulinemia seen between 2011 and 2016 was undertaken. The clinical and immunologic profile was determined for patients with confirmed or suspected SLE who also had undergone evaluation for humoral immunodeficiency.

Results We identified 40 patients meeting ACR criteria for SLE with inadequate response to pneumococcal vaccine challenge (failure to generate protective antibody titer to $\geq 5/14$ pneumococcal vaccine antigens) and/or low serum IgG levels (< 700 mg/dl) not attributable to antecedent immunosuppressive therapy. This comprised 5.0% of our SLE patients meeting ACR SLE criteria in active follow-up. An additional 37 patients with SLE clinical features but not meeting SLE ACR criteria were identified with low serum IgG and/or inadequate vaccine responses. Among the 40 identified patients meeting ACR SLE criteria, serum immunoglobulin levels ranged from 459–760 mg/dl; 36 (90%) had serum IgG levels < 700 mg/dl, while 24 (60%) had inadequate response to pneumococcal vaccine challenge, including the four patients with serum IgG > 700 mg/dl. Frequent upper/lower respiratory infections requiring antibiotic treatment (≥ 3 episodes/year) were reported in 25/40 (63%) patients. SLE features developed 2–26 years (mean = 8.9 years) prior to the recognition of low serum IgG in 27 (68%) patients, whereas initial SLE features were noted concurrently with or 3–4 years following first confirmed low IgG levels in 13 (33%). Arthritis (75%),

CE-43 FACTORS ASSOCIATED WITH NEUROPSYCHIATRIC INVOLVEMENT IN 1193 LATIN AMERICAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

1Leonor A Barile-Fabris*, **2Daniel Wojdyla**, **2Luis J Catoggio**, **2Hugo R Scherbarth**, **2Verónica Saurit**, **3Eloisa Bonfa**, **3Lilian T Lavras Costallat**, **3Fernando Cavalcanti**, **4José F Molina**, **5Gil Reyes-Llerena**, **6Loreto Massardo**, **1Mary C Amigo**, **1Luis H Silveira**, **7José L Alfaro**, **8Rosa Chacón**, **9Graciela S Alarcón**, **2Bernardo A Pons-Estel**. **1GLADEL Mexico**; **2GLADEL Argentina**; **3GLADEL Brasil**; **4GLADEL Colombia**; **5GLADEL Cuba**; **6GLADEL Chile**; **7GLADEL Peru**; **8GLADEL Venezuela**; **9GLADEL USA (associated)**

10.1136/lupus-2016-000179.121

Introduction Neuropsychiatric (NP) manifestations in SLE are a major cause of morbidity, mortality and long term consequences.

Factors related to their occurrence in patients with short disease duration, both early in the course of the disease and during follow up have not been clearly established.

Purpose To identify disease and non-disease related factors associated with NP manifestations in early SLE.

Methods We included 1193 patients from the GLADEL inception cohort free of NP involvement at cohort entry. We examined the relationship between socio-demographic, clinical and laboratory data as well as disease activity and damage with NP involvement during follow-up. Data were recorded in ARTHROS database. We excluded all the secondary NP manifestations (metabolic, drug induced, infectious, etc). **Statistical methods** The time from cohort entry to first NP manifestation was examined using a Cox proportional hazard regression model. Patients without NP manifestations were censored at last study visit. Independent factors associated with NP involvement were identified using a multivariable Cox regression model. Variables included in the final model were selected using a backward selection algorithm with α -level to stay in the model set to 0.05. Results are summarised as hazard ratios with 95% confidence intervals.

Results During a median follow-up time of 52 months, 238 (20%) patients had NP involvement. The cumulative incidence estimate of NP involvement at 1, 3 and 5 years was 8.3%, 17.8% and 24.7%, respectively. In the univariable analysis some variables like ethnic origin were found to be more frequent in mestizos as compared to patients in the other ethnic groups. Factors

Abstract CE-43 Table 1 Multivariate Model for Neurological Manifestations During Follow-Up

Variable	Parameter Estimate	Standard Error	Chi-Square	p-value	Hazard Ratio represents	Hazard Ratio	95% CI Hazard Ratio
Etnia (African Latin American)	0.53132	0.14438	13.5421	0.0002	Mestizo vs. White	1.701	1.282 2.258
Etnia (Other)	0.16647	0.22746	0.5357	0.4642	ALA vs. White	1.181	0.756 1.845
Disease Duration at Cohort Entry (Up to 6 Months)	0.31590	0.42454	0.5537	0.4568	Other vs. White	1.371	0.597 3.152
Disease Duration at Cohort Entry (6 to 12 months)	-0.32679	0.20764	2.4769	0.1155	Up to 6 Months vs. Entered at Diagnosis	0.721	0.480 1.083
Disease Duration at Cohort Entry (13 to 24 months)	-0.32704	0.20726	2.4898	0.1146	6 to 12 Months vs. Entered at Diagnosis	0.721	0.480 1.082
Disease Duration at Cohort Entry (13 to 24 months)	-0.44389	0.19168	5.3629	0.0206	13 to 24 Months vs. Entered at Diagnosis	0.642	0.441 0.934
Myalgias/Myositis	0.60551	0.16169	14.0235	0.0002	Yes vs. No	1.832	1.335 2.515
Pneumonitis	0.90663	0.42076	4.6429	0.0312	Yes vs. No	2.476	1.085 5.648
Shrunk lung	0.88727	0.41648	4.5387	0.0331	Yes vs. No	2.428	1.074 5.493
Hemolytic Anemia	0.48776	0.18645	6.8436	0.0089	Yes vs. No	1.629	1.130 2.347

independently associated with NP manifestations during follow up are listed in Table 1.

Conclusions There are both disease and non-disease related factors that are clearly associated with NP manifestations. Patients of Mestizo background, those with myositis and those with hemolytic anaemia are at higher risk of developing NP.

Features Predictive of the Occurrence of NP Manifestations by Multivariable Cox regression model

CE-45

BASELINE FACTORS PREDICTIVE OF THE OCCURRENCE OF NEUROPSYCHIATRIC DAMAGE ACCRUAL IN LATIN AMERICAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

¹Bernardo A Pons-Estel*, ²Daniel Wojdyla, ³Graciela S Alarcón, ⁴Guillermo J Pons-Estel, ⁵Manuel F Ugarte-Gil, ⁶Francisco Caeiro, ⁷Enrique R Soriano, ⁸Mercedes A García, ⁹João C Tavares Brenol, ¹⁰Eloisa Bonfa, ¹¹Fernando Cavalcanti, ¹²Gloria Vásquez, ¹³Marlene Guibert-Toledano, ¹⁴Oscar Neira, ¹⁵Mario H Cardiel, ¹⁶Virginia Pascual-Ramos, ¹⁷Maria I Segami M, ¹⁸Maria H Esteva-Spinetti, ¹⁹Leonor A Barile-Fabris. ¹Hospital Provincial de Rosario, Rosario, Argentina; ²GLADEL consultant, Rosario, Argentina; ³Department of Medicine, Division of Clinical Immunology and Rheumatology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States; ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Spain; ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Perú; ⁶Servicio de Reumatología, Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina; ⁷Sección de Reumatología, Servicio de Clínica Médica, Hospital Italiano and Fundación Dr. Pedro M. Catoggio para el Progreso de la Reumatología, Buenos Aires, Argentina; ⁸Hospital Interzonal General de Agudos "General San Martín", La Plata, Argentina; ⁹Hospital das Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil; ¹⁰Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; ¹¹Centro de Ciências da Saúde, Universidade Federal de Pernambuco, Brazil; ¹²Universidad de Antioquia, Hospital Universitario "San Vicente de Paul," Medellín, Colombia; ¹³Centro de Investigaciones Médico Quirúrgicas- CIMEQ, Havana, Cuba; ¹⁴Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile; ¹⁵Centro de Investigación Clínica de Morelia SC, Morelia, Michoacan, México; ¹⁶Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán," Ciudad de México, México; ¹⁷Hospital Nacional "Edgardo Rebagliatti Martins," Essalud, Lima, Perú; ¹⁸Hospital Central de San Cristóbal, San Cristóbal, Venezuela; ¹⁹Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México

10.1136/lupus-2016-000179.123

Background Neuropsychiatric (NP) manifestations of systemic lupus erythematosus (SLE) are an important source of morbidity, functional impairment and poor quality of life. Several investigators have examined predictors of overall damage accrual in SLE, but predictors of NP-damage have been infrequently evaluated. The aim of this study was to assess the socio-demographic and disease related factors predictive of the occurrence of NP-damage accrual and its impact on mortality in Latin-American SLE patients with early disease.

Materials and methods We included 1100 patients from the GLADEL (Grupo Latino Americano De Estudio del Lupus) inception cohort, free of NP involvement at cohort entry (baseline) (up to 2-years of disease duration). We examined the relationship between socio-demographic characteristics, early clinical manifestations, disease activity and treatments (during the first 6 months post-baseline), with the development of NP-damage after 6 months post-baseline. NP-damage was measured with the SLICC Damage Index or Neuro-Damage (cognitive impairment or major

CE-44 PSYCHOSIS DUE TO SYSTEMIC LUPUS ERYTHEMATOSUS IN BLACK CARIBBEAN PATIENTS

Cindy Flower*. University of the West Indies, Cave Hill campus, Barbados

10.1136/lupus-2016-000179.122

Background To determine the frequency, characteristics and long-term outcome of psychosis due to systemic lupus erythematosus (SLE) in a cohort of Barbadian patients.

Materials and methods All patients with 4 or more American College of Rheumatology (ACR) classification criteria for SLE along with a clinical diagnosis of lupus psychosis were included in the assessment. Patients were identified from rheumatology clinic data and the Barbados lupus registry. Analysis was restricted to events occurring between January 1985 and December 2015.

Results Lupus psychosis was diagnosed and treated in 28 of 376 patients (7.4%) making it the most common manifestation of neuropsychiatric lupus (NPSLE) in this group of patients. Most patients were female ($F = 27$) and the median age at diagnosis of lupus psychosis was 31 years. In 61% of patients the psychosis was a presenting feature or developed within a year of SLE diagnosis. Psychosis was part of a multisystemic involvement characterised by polyarthritis (84%), haematologic features (74.1%), serositis (50.3%), renal disease (47%)- the frequency of these complications being in keeping with that of the entire group of SLE patients. All patients had resolution of the psychotic symptoms within weeks of treatment. Lupus psychosis was not a direct contributor to mortality. The 18 deaths recorded were secondary to intercurrent illness – SLE nephritis (39%), stroke (28%) and infection (22%).

Conclusion Lupus psychosis is the most common characteristic of NPSLE in this group of Black Caribbean patients and is an early, highly responsive complication- typically occurring in the setting of multisystemic involvement. The long-term outcome of patients was generally not favourable because of concurrent complications which lead to death.